Recombinant human erythropoietin α targets intratumoral blood vessels, improving chemotherapy in human xenograft models

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7186-7193

  Tóvári, József ^a   Gilly, Réka ^a   Rásó, Erzsébet ^a   Paku, Sándor ^b   Bereczky, Bíborka ^a   Varga, Norbert ^a   Vágó, Ágnes ^a   Tímár, József ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPOETINUM ALPHA; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 23844507094     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2498     Document Type: Article

References (24)

1. Tchekmedyian NS. Anaemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002;1:17-24.
2. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001;91:2214-21.
4. Vaupel P, Kelleher DK, Höckel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28: 29-35.
5. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
6. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974-8.
7. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
8. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001;98: 5181-6.
9. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4: 459-60.
10. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003;21:169-80.
11. Blackwell KL, Kirkpatrik JP, Snyder SA, et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 2003;63:6162-5.
12. Golab J, Olszewska D, Móz P, et al. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin Cancer Res 2002;8:1265-70.
13. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61: 1358-61.
14. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28:49-53.
15. ten Hagen TL, Eggermont AM. Manipulation of the tumour-associated vasculature to improve tumour therapy. J Liposome Res 2002;12:149-54.
16. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83: 1477-87.
17. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999-1007.
18. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001;84: 836-43.
19. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978-82.
20. Carlini RG, Alonzo EJ, Domingez J, et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 2002;55:546-53.
21. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck K-H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33.
22. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93: 2627-36.
23. Dome B, Paku S, Somla B, Tímár J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002;197:355-62.
24. Belelin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi TT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-80.